Menu
16.6.2026 07:00:01 CEST | Thor Medical ASA | Non-regulatory press releases
Thor Medical ASA today announced that Dr. Alf Bjørseth will retire from his position as EVP Business Development effective June 30, 2026.
Dr. Bjørseth previously served as CEO of Thor Medical and has been instrumental in the development of the company. At 84 years of age, he has decided to step down from his executive position.
“Alf has played an important role in the development of Thor Medical. I would like to thank him for his commitment to the company. Knowing Alf, I’m sure he will stay engaged and follow the development as we continue our further progress,” said CEO of Thor Medical, Jasper C. Kurth.
For further information, please contact:
Thor Medical ASA
Mathias Nilsen Reierth, Head of Communications and Corporate Affairs
+47 988 05 724, mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium, a key component of next-generation targeted cancer treatment. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides a reliable, environmentally friendly and cost-efficient supply of alpha emitters to the radiopharmaceutical industry. Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by fueling next-generation cancer therapies with high-purity isotopes. Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit www.thormedical.com - https://www.thormedical.com.
